Meridian Bioscience (VIVO) Misses Q1 EPS by 5c; Lowers Outlook, Cuts Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward
January 25, 2017 7:30 AM ESTGENERAL HIGHLIGHTS
CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year; reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases... More